SEC Comment Letter 0000000000-23-011159 to Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: Oct. 12, 2023 · CIK: 0001643918 · Accession: 0000000000-23-011159
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274895
Letter
United States securities and exchange commission logo October 12, 2023 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals Plc 1 Caspian Point Caspian Way Cardiff, CF10 4DQ, UK Re:Biodexa Pharmaceuticals Plc Registration Statement on Form F-1 Filed October 6, 2023 File No. 333-274895 Dear Stephen Stamp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jason McCaffrey, Esq.
Show Raw Text
United States securities and exchange commission logo
October 12, 2023
Stephen Stamp
Chief Executive Officer
Biodexa Pharmaceuticals Plc
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ, UK
Re:Biodexa Pharmaceuticals Plc
Registration Statement on Form F-1
Filed October 6, 2023
File No. 333-274895
Dear Stephen Stamp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jason McCaffrey, Esq.